abstract: This script gives a pragmatic advice for dentists on pain control and anti-inflammation treatment considering current literature and state of the art of analgesic treatment. Naproxen seems to be the feasible anti-inflammatory painkiller as it has a lower cardio-vascular risk profile compared to other NSAID. The higher gastrointestinal bleeding risk can be mitigated using proton-pump inhibitors. Additionally, the duration of the drug effect of about 1215 hours allows excellent patient compliance and comfort in comparison to other NSAID.
authors.affiliation: Clinique et policlinique de chirurgie buccale et maxillofaciale, Centre de médecine dentaire, Université de Zurich, Zurich, Switzerland.
authors.forename: Claudio
authors.initials: C
authors.lastname: Rostetter
authors.forename: Heinz-Theo
authors.initials: HT
authors.lastname: Lübbers
authors.forename: Philipp
authors.initials: P
authors.lastname: Metzler
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects* / Q000627:therapeutic use*; D005240:Feasibility Studies; D007052:Ibuprofen / Q000009:adverse effects / Q000627:therapeutic use; D008528:Mefenamic Acid / Q000009:adverse effects / Q000627:therapeutic use; D009288:Naproxen / Q000009:adverse effects / Q000627:therapeutic use; D059408:Pain Management / Q000379:methods*; D014098:Toothache / Q000188:drug therapy*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D008528:Mefenamic Acid; D009288:Naproxen; D007052:Ibuprofen
keywords: Traitement analgésique; naproxène; anti-inflammatoires non stéroïdiens